Results of a randomized, double‐blind, active‐controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder
ConclusionsPropiverine ER 30 mg was confirmed to be an effective and well‐tolerated treatment option for patients with OAB symptoms. This first head‐to‐head study showed non‐inferiority of propiverine ER 30 mg compared with tolterodine ER 4 mg.
Can be inserted under skin to stimulate sacral nerve, says NICE Related items fromOnMedica Surgical mesh last resort for prolapse or incontinence Pelvic organ prolapse Strong women ’s rights linked to better health Hundreds of women take legal action over vaginal mesh implants Surgical options must be ‘last resort’ for stress incontinence
The objective this study is to publish the study protocol that aims to investigate whether urgency decreases after treatment with both of the techniques.MethodsThis randomized controlled clinical trial will include 99 women, aged more than 18 years old, with urgency (score ≥ 8 in the Overactive Bladder-Validated 8-Question Awareness Tool [OAB-V8]). Women will be randomly allocated into three groups: TTNS, PTES, and placebo. The following questionnaires will be applied: the Anamnesis Record, the Incontinence Questionnaire Overact ive Bladder, the King’s Health Questionnaire, the 24-Hour Voidin...
Publication date: Available online 31 January 2020Source: Annals of Physical and Rehabilitation MedicineAuthor(s): C. Hentzen, A. Villaumé, N. Turmel, G. Miget, F Le Breton, C. Chesnel, G. AmarencoAbstractBackground: Urgency urinary incontinence is one of the major disabling urinary symptoms in people with multiple sclerosis (PwMS). The warning time (time from first sensation of urgency to voiding or incontinence) only partially reflects the possibility of continence. Other factors such as mobility, difficulties in transfer or undressing can influence this time.Objectives: The aim was to create a specific test for P...
Conclusions Our study suggests that minority race and ethnicity may be associated with worse performance on certain UDS parameters. Future studies should aim to understand if these differences are due to genetic, disease-related, behavioral, and/or socioeconomic factors and whether these differences are associated with worse subjective OAB.
Overactive bladder (OAB) is a symptom complex that includes urinary urgency, frequency, urgency incontinence, and nocturia. It is highly prevalent, affecting up to 12% of the adult population, and can significantly impact quality of life. The diagnosis of OAB is made by history, physical examination, and a urinalysis to rule out underlying infection or other concerning potential etiologies. The need for additional testing is based on the initial evaluation findings, and is recommended in cases of underlying urinary tract infection, microscopic hematuria, obstructive voiding symptoms, and symptoms refractory to previous treatments.
Pelvic floor disorders (PFD) including stress urinary incontinence (SUI), overactive bladder (OAB) symptoms, anal incontinence (AI), pelvic organ prolapse (POP) and sexual dysfunction affect millions of women throughout the world. Studies have shown that 11%-35.5% of women suffer from PFD ’s globally [1,2]. In developed countries, 25% of women experience at least one or more PFD’s . Evidence from these countries shows that advancing age, parity, obesity and vaginal birth are common risk factors of PFD’s.
ConclusionsThe PRR in studies of OAB is varied and significant. It is clear that it can be affected by factors in study design including type of bladder diary. When designing clinical studies this should be borne in mind. Equally, when attempting to optimise patient care, the benefit of the therapeutic encounter should be remembered.
Condition: Urinary Urgency Incontinence Intervention: Device: Neuspera Implantable Sacral Nerve Stimulation System Sponsor: Neuspera Medical, Inc. Not yet recruiting
Conclusions: This meta-analysis indicated that BTX-A 200U and 300U are more effective than placebo in the treatment of NDO, with minimal, local, and manageable adverse events. Furthermore, BTX-A 300U and 200U could also improve detrusor compliance of IOAB. However, more RCTs would still be necessary to explore the effect of BTX-A on management of UI in NDO and IOAB patients.
The sacral neuromodulation market continues to see disruption as Medtronic scores a CE markÂ for itsÂ InterStim Micro neurostimulator and InterStim SureScan MRI leads, clearing the technologies for sale in Europe. InterStim Micro is a rechargeable device that delivers sacral neuromodulation (SNM) therapy to treat overactive bladder (OAB), fecal incontinence (FI) and non-obstructive urinary retention. It is 80% smaller than the existing recharge-free InterStim II neurostimulator and could reduce the need for battery replacement surgeries due to its life of 15 years. It also features Medtronic'sÂ&...